Advertisement

Acta Neuropathologica

, Volume 120, Issue 1, pp 33–41 | Cite as

FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration

  • Hazel Urwin
  • Keith A. Josephs
  • Jonathan D. Rohrer
  • Ian R. Mackenzie
  • Manuela Neumann
  • Astrid Authier
  • Harro Seelaar
  • John C. Van Swieten
  • Jeremy M. Brown
  • Peter Johannsen
  • Jorgen E. Nielsen
  • Ida E. Holm
  • The FReJA Consortium
  • Dennis W. Dickson
  • Rosa Rademakers
  • Neill R. Graff-Radford
  • Joseph E. Parisi
  • Ronald C. Petersen
  • Kimmo J. Hatanpaa
  • Charles L. White III
  • Myron F. Weiner
  • Felix Geser
  • Vivianna M. Van Deerlin
  • John Q. Trojanowski
  • Bruce L. Miller
  • William W. Seeley
  • Julie van der Zee
  • Samir Kumar-Singh
  • Sebastiaan Engelborghs
  • Peter P. De Deyn
  • Christine Van Broeckhoven
  • Eileen H. Bigio
  • Han-Xiang Deng
  • Glenda M. Halliday
  • Jillian J. Kril
  • David G. Munoz
  • David M. Mann
  • Stuart M. Pickering-Brown
  • Valerie Doodeman
  • Gary Adamson
  • Shabnam Ghazi-Noori
  • Elizabeth M. C. Fisher
  • Janice L. Holton
  • Tamas Revesz
  • Martin N. Rossor
  • John Collinge
  • Simon Mead
  • Adrian M. Isaacs
Open Access
Original Paper

Abstract

Through an international consortium, we have collected 37 tau- and TAR DNA-binding protein 43 (TDP-43)-negative frontotemporal lobar degeneration (FTLD) cases, and present here the first comprehensive analysis of these cases in terms of neuropathology, genetics, demographics and clinical data. 92% (34/37) had fused in sarcoma (FUS) protein pathology, indicating that FTLD-FUS is an important FTLD subtype. This FTLD-FUS collection specifically focussed on aFTLD-U cases, one of three recently defined subtypes of FTLD-FUS. The aFTLD-U subtype of FTLD-FUS is characterised clinically by behavioural variant frontotemporal dementia (bvFTD) and has a particularly young age of onset with a mean of 41 years. Further, this subtype had a high prevalence of psychotic symptoms (36% of cases) and low prevalence of motor symptoms (3% of cases). We did not find FUS mutations in any aFTLD-U case. To date, the only subtype of cases reported to have ubiquitin-positive but tau-, TDP-43- and FUS-negative pathology, termed FTLD-UPS, is the result of charged multivesicular body protein 2B gene (CHMP2B) mutation. We identified three FTLD-UPS cases, which are negative for CHMP2B mutation, suggesting that the full complement of FTLD pathologies is yet to be elucidated.

Keywords

FTLD FUS FTLD-UPS Frontotemporal FTD 

Abbreviations

bvFTD

Behavioural variant FTD

CHMP2B

Charged multivesicular body protein 2B

FTD

Frontotemporal dementia

FTD-3

FTD linked to chromosome 3

FTLD

Frontotemporal lobar degeneration

FTLD-IF

Frontotemporal lobar degeneration with intermediate filament positive inclusions

FTLD-ni

Frontotemporal lobar degeneration with no inclusions

FTLD-TDP

Frontotemporal lobar degeneration with TDP-43 positive inclusions

FTLD-UPS

Frontotemporal dementia with ubiquitin positive, TDP-43 negative inclusions

GRN

Progranulin

MAPT

Microtubule associated protein tau

NCI

Neuronal cytoplasmic inclusion

NII

Neuronal intranuclear inclusion

PPA

Primary progressive aphasia

TDP-43

Transactive response binding protein of 43 kDa

VCP

Valosin containing protein

Introduction

Frontotemporal lobar degeneration (FTLD) describes a group of diseases characterised by bilateral, often asymmetric, atrophy of the frontal and anterior temporal lobes. Frontotemporal dementia (FTD), also termed behavioural variant FTD (bvFTD), is the most common clinical manifestation, but FTLD can also cause the language disorders progressive non-fluent aphasia (PNFA) and semantic dementia (SD), collectively known as primary progressive aphasia (PPA). The clinical presentation is related to the distribution of pathology in the frontal and temporal lobes. Despite gross pathological similarities, FTLD comprises a clinically, genetically, and neuropathologically heterogeneous collection of disorders.

A family history of a similar disease has been reported in 25–40% of FTLD cases [6, 44, 50], although this estimate is much lower in some populations [17]. FTLD-causing mutations have been found in the microtubule-associated protein tau (MAPT) [16], progranulin (GRN) [1, 7] and charged multivesicular body protein 2B (CHMP2B) genes [49]. Mutations in valosin-containing protein (VCP) cause inclusion body myopathy and Paget disease of bone with frontotemporal dementia, in which 20–100% of patients can develop FTD [10, 53, 56]. GRN mutations account for approximately 10% of FTLD cases [2, 7, 8, 9] and MAPT up to 10% depending on the population studied [15, 41, 48]; while mutations in CHMP2B are a much rarer cause of FTLD, having been reported in one Danish family termed frontotemporal dementia linked to chromosome 3 (FTD-3) [25, 49, 52] and one unrelated Belgian familial FTLD patient [54].

Up to 40% of FTLD cases, including all MAPT mutation cases, have tau pathology [48] (FTLD-tau); while over 50% have neuronal inclusions, which are immunoreactive for ubiquitin in the absence of abnormal tau, α-synuclein, or amyloid deposition [20]. In the majority of tau-negative cases, the major ubiquitinated protein is the TAR DNA-binding protein 43 (TDP-43) [11, 39], and these are designated FTLD-TDP [30]. FTLD-TDP can be further classified into neuropathological subtypes depending on the distribution, morphology and precise cellular location of inclusions [28, 45].

Recent studies report that 6–20% of tau-negative FTLD cases have ubiquitinated inclusions which are TDP-43 negative [12, 21, 29, 42]. Ubiquitin positive, tau and TDP-43 negative cases include those with neuronal intermediate filament- and α-internexin-positive inclusions [5, 19], termed NIFID, and basophilic inclusion body disease (BIBD) [35, 58]. Distinct from these are a subset of FTLD cases termed atypical FTLD-U (aFTLD-U), which do not have intermediate filament positive or basophilic inclusions, but are characterised by unusual curved or twisted neuronal intranuclear ubiquitin positive inclusions, as well as cytoplasmic inclusions [29, 42]. The recent finding of FUS (fused in sarcoma) protein pathology in aFTLD-U cases [37] and subsequently in NIFID and BIBD cases [34, 38] has led to further reorganisation of FTLD classification [31]: aFTLD-U, NIFID and BIBD are now considered three distinct subtypes of FTLD-FUS, the collective term for FTLD cases with FUS pathology. Cases with ubiquitinated inclusions that are negative for tau, TDP-43 and FUS are termed FTLD-UPS [30]; this includes FTLD cases caused by CHMP2B mutations [13, 14].

FUS pathology was first described in familial ALS cases following the discovery of causative mutations in the FUS gene [23, 55]. FUS is a multifunctional DNA- and RNA-binding protein, sharing functional homology with TDP-43 [24]. FUS pathology has also been found in polyglutamine expansion diseases including Huntington’s disease, suggesting a broad spectrum of FUS proteinopathies [34, 38, 57]. However, FUS pathology was not found in FTD-3, a major subtype of FTLD-UPS [14].

A minority of cases do not have tau, TDP-43, FUS or ubiquitinated inclusions and these have been termed FTLD with no inclusions (FTLD-ni, previously dementia lacking distinctive histopathology, or DLDH) [30]. Increasingly sensitive immunostaining protocols have led to most FTLD-ni cases being reclassified [20, 26, 32]; however, a small group remain negative for characterised inclusions despite the use of updated ubiquitin immunohistochemistry.

Here, we report, through a major international collaboration, the first comprehensive collection of the aFTLD-U subtype of FTLD-FUS and describe their clinical and demographic features.

Materials and methods

Cases

A total of 37 cases with ubiquitin-positive but tau- and TDP-43-negative inclusions were evaluated from 12 academic research centres. In each centre, clinical information was acquired from case notes by a neurologist with expertise in neurodegenerative diseases. Standard neurological and cognitive assessments were used to ascertain the presence of behavioural, cognitive and motor abnormalities. All centres followed consensus clinical criteria for FTLD diagnosis [33, 36], and were asked to supply presenting symptoms for each patient and the final clinical diagnosis that had been rendered by the evaluating neurologist. These data were collated and then reviewed by an expert in FTLD (K.A.J.) to ensure consistency in diagnosis among the different centres. BIBD and NIFID cases were specifically excluded in order to focus on a specific subtype of FTLD-FUS. Twenty-three cases for which DNA was available (21 FTLD-FUS and 2 FTLD-UPS) were screened for CHMP2B mutations. Fifteen FTLD-FUS cases were screened for FUS mutations and a further six have been reported previously as FUS mutation negative [37]. Patients were considered to have a family history if a first- or second-degree relative had dementia. This study was approved by the UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery Local Research Ethics Committee.

Histopathology

All cases were stained for TDP-43, ubiquitin and α-internexin or neurofilament proteins according to local protocols at each centre [2, 12, 21, 27, 29, 39, 40, 42, 47, 53]. Experienced neuropathologists in each centre analysed the sections to give the neuropathological diagnosis. FUS staining was subsequently performed on frontal cortex and hippocampus for all cases. As previously described, FUS staining is sensitive to length of fixation [37]. Therefore, at least two antibodies (Sigma HPA008784 and Bethyl Laboratories A300-302A) were used for all cases examined and antibody concentrations optimised for each case by ensuring physiological FUS staining was visible, as recommended in the original description of FTLD-FUS [37]. To further ensure inter-centre reliability 26 cases, including the three remaining FTLD-UPS cases, were stained in one of two laboratories which first reported FTLD-FUS (IRM or MN).

Genetic analysis

Genomic DNA was extracted from brain tissue using standard phenol–chloroform extraction, or DNA extracted from brain or blood was directly provided by the contributor. The entire open reading frame and exon–intron boundaries of CHMP2B and FUS were sequenced, except for three cases in which FUS exons 14 and 15 only were sequenced. Primers and conditions for CHMP2B sequencing have been described previously [49]; conditions for FUS sequencing are available on request. Sequences were analysed using the SeqScape software Version 2.5 (Applied Biosystems, Foster City, CA, USA).

Results

Neuropathology

A total of 37 ubiquitin-positive, tau- and TDP-43-negative cases were examined. 92% (34/37) of cases were characterised by neuronal cytoplasmic and intranuclear inclusions (NIIs) which were immunoreactive for FUS, corresponding to the aFTLD-U subtype of FTLD-FUS. The NIIs were as previously described, having an unusual morphology, which can be long and straight, curved or twisted [29, 42]. Striatal degeneration was present in 100% (27/27) of aFTLD-U cases and hippocampal sclerosis was present in 97% (29/30) of cases. 8% (3/37) were characterised by ubiquitin-positive neuronal cytoplasmic inclusions (NCIs) which were FUS-negative, i.e. FTLD-UPS.

Genetics

Sequencing of the CHMP2B gene in all cases for which DNA was available revealed no further coding mutations. Two synonymous coding variants were identified in three FTLD-FUS cases: c.27C>T, p.Thr9Thr and c.372A>C, p.Thr124Thr. These two variants were each observed in the heterozygous state but always together, suggesting they could be in linkage disequilibrium. None of these variants has been previously reported, but as they do not lead to an amino acid change, they are unlikely to be pathogenic. Therefore, CHMP2B mutation-positive cases comprise a distinct genetic subgroup of FTLD-UPS. No mutations were identified in FUS in any case.

Demographics

Onset

Age at onset data was available for 33 aFTLD-U cases. The mean age of onset was 41.2 years (standard deviation 9.3 years). The three FTLD-UPS cases had a mean age of onset of 50.3 years (standard deviation 4 years).

Disease duration

Disease duration data were available for 33 aFTLD-U cases. Mean disease duration was 7.7 years (standard deviation 3.2 years). Disease duration data were available for only two of the three FTLD-UPS cases and were 4 and 11 years, respectively.

Sex

Of the aFTLD-U cases, 47% (16/34) were female and all three FTLD-UPS cases were female.

Family history

One aFTLD-U case (3%, 1/34) had a family history and 2/3 of the FTLD-UPS cases had positive family histories.

Clinical features

The clinical features of several aFTLD-U cases have previously been reported [21, 29, 42, 46] and analysed together, these cases form a clinically homogeneous group. 94% (32/34) of aFTLD-U patients received an initial diagnosis of bvFTD (Table 1). The other two patients, for whom there was little clinical information available, were described as having ‘unspecified dementia’. Patients were typically described as showing a decline in social conduct, self-neglect and disinhibition, with aggression as a common feature. Inappropriate sexual behaviour was widely reported, in 52% of cases (12/23) (Table 1). Dietary changes, most commonly overeating, were observed in 81% of cases (21/26) with hyperorality a feature of several.
Table 1

Clinical symptoms in aFTLD-U cases

ID

Sex

Diagnosis

Behavioural/personality

Psychiatric

Cognitive

Motor

Apathy

Disinh

Abnormal eating

Compulsions

Inappropriate sexual

Delusions

Hallucinations

Aphasia

Parkinsonism

MND

UBC1

F

bvFTD

1

1

1

1

0

0

0

0

0

0

UBC2

F

bvFTD

1

0

0

0

1

1

0

0

0

0

UBC3

F

bvFTD

1

1

1

0

1

0

0

0

0

0

UBC4

F

bvFTD

1

1

1

0

0

0

0

0

0

0

UBC5

M

bvFTD

1

1

1

0

1

1

0

0

0

0

UBC6

F

bvFTD

1

1

0

0

0

0

1

0

0

0

MUC1

M

Dem

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

MUC2

F

bvFTD

1

1

0

0

NA

NA

NA

1

0

0

MUC3

F

Dem

NA

1

NA

NA

NA

NA

NA

NA

NA

NA

MUC4

M

bvFTD

1

1

1

1

NA

NA

NA

1

0

0

MUC5

F

bvFTD

0

1

1

0

NA

NA

NA

1

0

0

MUC6

M

bvFTD

1

1

NA

NA

NA

NA

NA

NA

NA

NA

MUC7

F

bvFTD

1

1

1

0

0

0

0

0

0

0

MUC8

M

bvFTD

NA

1

NA

NA

NA

NA

NA

NA

NA

NA

MUC9

M

bvFTD

0

1

1

1

NA

NA

NA

0

0

0a

UR1

M

bvFTD

1

1

1

1

1

0

1

0

0

0

UR2

F

bvFTD

1

1

1

0

1

0

0

0

0

0

UR3

F

bvFTD

1

NA

1

1

0

1

0

0

0

0

UR4

F

bvFTD

1

1

0

1

0

0

0

0

0

0

UT1

M

bvFTD

NA

1

NA

NA

NA

1

0

0

0

0

UTSW1

M

bvFTD

1

1

1

1

1

0

0

1

0

0

NWU1

M

bvFTD

0

1

1

1

1

0

0

0

0

0

NWU2

F

bvFTD

1

1

1

1

1

0

0

1

0

0

UP1

F

bvFTD

1

1

1

1

0

NA

NA

0

0

0

UP2

M

bvFTD

1

0

1

1

0

NA

NA

0

0

0

UP3

M

bvFTD

1

1

NA

1

0

NA

NA

0

0

0

UNSW1

F

bvFTD

NA

1

NA

1

NA

0

0

1

1

0

UNSW2

M

bvFTD

NA

1

1

0

0

0

0

1

0

0

MC1

M

bvFTD

0

1

1

1

1

0

1

0

0

0

MC2

F

bvFTD

0

1

NA

1

1

NA

NA

0

0

0

MC3

M

bvFTD

0

1

1

1

1

0

0

0

0

0

MC4

M

bvFTD

1

0

0

1

0

0

0

0

0

0

MC5

M

bvFTD

0

1

1

0

1

0

0

0

0

0

UCL1

M

bvFTD

NA

1

1

NA

NA

0

1

NA

0

0

  

% with symptom

74

91

81

61

52

18

18

24

3

0

Cases of aFTLD-U were scored for presence of the symptoms indicated

0 absent, 1 present, NA information not available, bvFTD behavioural variant FTD, Dem unspecified dementia, Disinh disinhibition

aOne patient exhibited tongue fasciculation, dysphagia and muscle hypotonia but there was insufficient evidence to diagnose MND

Strikingly, psychotic symptoms, either hallucinations or delusions, were observed in 36% of aFTLD-U patients (8/22), and not comorbid in any case. Motor symptoms were infrequent and when present, they were typically limited to mild rigidity or intermittent hyperkinesias. Only one patient (1/30, 3%) showed classical parkinsonism.

The three FTLD-UPS cases all had an initial diagnosis of bvFTD. Very little clinical information was available, but apathy was common to two of these cases as was parkinsonism.

Discussion

This study describes the first comprehensive collection of the aFTLD-U subtype of FTLD-FUS. We show that aFTLD-U has a distinct clinical phenotype characterised by the behavioural variant FTD syndrome, a young onset of disease, a high prevalence of psychotic symptoms and a low prevalence of motor symptoms. FUS pathology accounted for 92% of cases with ubiquitin-positive, tau- and TDP-43-negative FTLD showing that it defines the vast majority of such cases. However, we identified three FTLD-UPS cases without CHMP2B mutation showing that while such cases are rare, the FTLD-UPS classification has not been completely subsumed by CHMP2B mutation cases or FTLD-FUS.

Of all of the FTLD subtypes, bvFTD is pathologically the most heterogeneous making it difficult to predict the underlying pathology from clinical features in life. This cohort similarly has an overlapping range of symptoms with other sporadic and genetic causes of bvFTD. However, psychotic symptoms are rarely described in other cases of bvFTD [22], and the presence of delusions and hallucinations in a substantial proportion of this cohort may help to distinguish them from other patients. The very low frequency of motor symptoms may also help define this group of patients.

The mean age of onset of 41.2 years for the aFTLD-U cases is much lower than that of a previously reported sporadic FTLD cohort (60.5 years) [4], and therefore, may help distinguish them from other sporadic FTLD cases. 15/34 aFTLD-U cases came from two contributing centres, therefore, it is possible that the results have been biassed by these cases, which were previously reported to have a low age of onset [29, 42]. However, the age of onset of these cases is not significantly different from the other 19 cases in the study (t test, ns). Furthermore, psychotic symptoms are evenly distributed between cases from these two centres (3/7, 42%) and cases from other centres (5/15, 33%) (Fisher’s exact test, ns).

Only one aFTLD-U case (3%, 1/34) had a positive family history for FTD: this patient was one of nine siblings, and had one brother who was diagnosed clinically with ‘Pick’s disease’ at 61 years of age and died at 64 years of age without autopsy. Another brother was reported to show ‘cognitive changes’ at the age of 64 years. The patient was negative for FUS mutation, suggesting that there may be other genetic causes of FTLD-FUS. While aFTLD-U cases have a distinctive and consistent clinico-pathological phenotype, FTLD appears to occur sporadically in the majority of cases. Of the three FTLD-UPS cases, two had a family history, and one had at least two relatives affected with the same disease [43]. These cases were negative for CHMP2B mutations, which suggests other genetic causes of FTLD-UPS and the possibility of at least one other unidentified ubiquitinated protein associated with FTLD. No gender bias was found in any of the groups studied. A female preponderance was previously reported in an analysis of a subset of aFTLD-U cases [29]; however, this was not confirmed in wider analysis.

It has recently been shown that two rare subtypes of FTLD, NIFID and BIBD have extensive FUS pathology [34, 38]. We did not include NIFID and BIBD cases in this study as they have been described to have distinct clinical features to aFTLD-U cases, particularly prominent motor symptoms [3, 18, 19, 34, 51, 58]. In order to allow comparison of FTLD-FUS to other FTLD cases, we focussed on one subtype of FTLD-FUS (aFTLD-U), as it is possible that FTLD-FUS comprises a clinically heterogeneous group. However, now that NIFID, BIBD and aFTLD-U have been shown to have a common underlying pathology, it will be interesting to directly compare these different FUS entities in future studies. FUS pathology is also found in polyglutamine expansion diseases including Huntington’s disease [57], showing that it is not limited to the FTLD-MND spectrum of diseases. This is similar to tau and TDP-43 pathology, which are pathological hallmarks of different FTLD subtypes but are also observed in a wide range of other neurodegenerative diseases. Within the clinical syndrome of FTLD, FUS pathology will be an extremely important tool for the classification of cases which are tau- and TDP-43- negative, and wider analysis of FTLD-FUS cases may reveal further subtypes.

In conclusion, the vast majority of cases with tau- and TDP-43 negative inclusions have FUS pathology, suggesting that FTLD-FUS is an important FTLD subtype. The opportunity to analyse a large series of aFTLD-U cases has only been possible through a large multi-centre collaboration, with all centres contributing a relatively small number of cases. This collaborative effort has provided new insights into the genetic and clinicopathological spectrum of FTLD-FUS and FTLD-UPS.

Notes

Conflict of interest statement

The authors report no conflicts of interest.

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

  1. 1.
    Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, Cannon A, Dwosh E, Neary D, Melquist S, Richardson A, Dickson D, Berger Z, Eriksen J, Robinson T, Zehr C, Dickey CA, Crook R, McGowan E, Mann D, Boeve B, Feldman H, Hutton M (2006) Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442:916–919CrossRefPubMedGoogle Scholar
  2. 2.
    Beck J, Rohrer JD, Campbell T, Isaacs A, Morrison KE, Goodall EF, Warrington EK, Stevens J, Revesz T, Holton J, Al Sarraj S, King A, Scahill R, Warren JD, Fox NC, Rossor MN, Collinge J, Mead S (2008) A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain 131:706–720CrossRefPubMedGoogle Scholar
  3. 3.
    Cairns NJ, Grossman M, Arnold SE, Burn DJ, Jaros E, Perry RH, Duyckaerts C, Stankoff B, Pillon B, Skullerud K, Cruz-Sanchez FF, Bigio EH, Mackenzie IR, Gearing M, Juncos JL, Glass JD, Yokoo H, Nakazato Y, Mosaheb S, Thorpe JR, Uryu K, Lee VM, Trojanowski JQ (2004) Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology 63:1376–1384PubMedGoogle Scholar
  4. 4.
    Cairns NJ, Neumann M, Bigio EH, Holm IE, Troost D, Hatanpaa KJ, Foong C, White CL III, Schneider JA, Kretzschmar HA, Carter D, Taylor-Reinwald L, Paulsmeyer K, Strider J, Gitcho M, Goate AM, Morris JC, Mishra M, Kwong LK, Stieber A, Xu Y, Forman MS, Trojanowski JQ, Lee VM, Mackenzie IR (2007) TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol 171:227–240CrossRefPubMedGoogle Scholar
  5. 5.
    Cairns NJ, Uryu K, Bigio EH, Mackenzie IRA, Gearing M, Duyckaerts C, Yokoo H, Nakazato Y, Jaros E, Perry RH, Arnold SE, Lee VMY, Trojanowski JQ (2004) alpha-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. Acta Neuropathol 108:213–223CrossRefPubMedGoogle Scholar
  6. 6.
    Chow TW, Miller BL, Hayashi VN, Geschwind DH (1999) Inheritance of frontotemporal dementia. Arch Neurol 56:817–822CrossRefPubMedGoogle Scholar
  7. 7.
    Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghe R, Dermaut B, Martin JJ, van Duijn C, Peeters K, Sciot R, Santens P, De Pooter T, Mattheijssens M, Van den Broeck M, Cuijt I, Vennekens K, De Deyn PP, Kumar-Singh S, Van Broeckhoven C (2006) Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442:920–924CrossRefPubMedGoogle Scholar
  8. 8.
    Cruts M, Van Broeckhoven C (2008) Loss of progranulin function in frontotemporal lobar degeneration. Trends Genet 24:186–194CrossRefPubMedGoogle Scholar
  9. 9.
    Gass J, Cannon A, Mackenzie IR, Boeve B, Baker M, Adamson J, Crook R, Melquist S, Kuntz K, Petersen R, Josephs K, Pickering-Brown SM, Graff-Radford N, Uitti R, Dickson D, Wszolek Z, Gonzalez J, Beach TG, Bigio E, Johnson N, Weintraub S, Mesulam M, White CL III, Woodruff B, Caselli R, Hsiung GY, Feldman H, Knopman D, Hutton M, Rademakers R (2006) Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet 15:2988–3001CrossRefPubMedGoogle Scholar
  10. 10.
    Guyant-Marechal L, Laquerriere A, Duyckaerts C, Dumanchin C, Bou J, Dugny F, Le Ber I, Frebourg T, Hannequin D, Campion D (2006) Valosin-containing protein gene mutations: clinical and neuropathologic features. Neurology 67:644–651CrossRefPubMedGoogle Scholar
  11. 11.
    Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, Beach TG, Buratti E, Baralle F, Morita M, Nakano I, Oda T, Tsuchiya K, Akiyama H (2008) Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol 64:60–70CrossRefPubMedGoogle Scholar
  12. 12.
    Hatanpaa KJ, Bigio EH, Cairns NJ, Womack KB, Weintraub S, Morris JC, Foong C, Xiao G, Hladik C, Mantanona TY, White CL III (2008) TAR DNA-binding protein 43 immunohistochemistry reveals extensive neuritic pathology in FTLD-U: a midwest-southwest consortium for FTLD study. J Neuropathol Exp Neurol 67:271–279CrossRefPubMedGoogle Scholar
  13. 13.
    Holm IE, Englund E, Mackenzie IR, Johannsen P, Isaacs AM (2007) A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3. J Neuropathol Exp Neurol 66:884–891CrossRefPubMedGoogle Scholar
  14. 14.
    Holm IE, Isaacs AM, Mackenzie IRA (2009) Absence of FUS-immunoreactive pathology in frontotemporal dementia linked to chromosome 3 (FTD-3) caused by mutation in the CHMP2B gene. Acta Neuropathol 118:719–720CrossRefPubMedGoogle Scholar
  15. 15.
    Houlden H, Baker M, Adamson J, Grover A, Waring S, Dickson D, Lynch T, Boeve B, Petersen RC, Pickering-Brown S, Owen F, Neary D, Craufurd D, Snowden J, Mann D, Hutton M (1999) Frequency of tau mutations in three series of non-Alzheimer’s degenerative dementia. Ann Neurol 46:243–248CrossRefPubMedGoogle Scholar
  16. 16.
    Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J, Basun H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Hayward N, Kwok JB, Schofield PR, Andreadis A, Snowden J, Craufurd D, Neary D, Owen F, Oostra BA, Hardy J, Goate A, van Swieten J, Mann D, Lynch T, Heutink P (1998) Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393:702–705CrossRefPubMedGoogle Scholar
  17. 17.
    Ikeda K (2000) Neuropatholl discrepancy between Japanese Pick’s disease without Pick bodies and frontal lobe degeneration type of frontotemporal dementia proposed by Lund and Manchester Group. Neuropathology 20:76–82CrossRefPubMedGoogle Scholar
  18. 18.
    Ishihara K, Araki S, Ihori N, Shiota J, Kawamura M, Nakano I (2006) An autopsy case of frontotemporal dementia with severe dysarthria and motor neuron disease showing numerous basophilic inclusions. Neuropathology 26:447–454CrossRefPubMedGoogle Scholar
  19. 19.
    Josephs KA, Holton JL, Rossor MN, Braendgaard H, Ozawa T, Fox NC, Petersen RC, Pearl GS, Ganguly M, Rosa P, Laursen H, Parisi JE, Waldemar G, Quinn NP, Dickson DW, Revesz T (2003) Neurofilament inclusion body disease: a new proteinopathy? Brain 126:2291–2303CrossRefPubMedGoogle Scholar
  20. 20.
    Josephs KA, Holton JL, Rossor MN, Godbolt AK, Ozawa T, Strand K, Khan N, Al-Sarraj S, Revesz T (2004) Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. Neuropathol Appl Neurobiol 30:369–373CrossRefPubMedGoogle Scholar
  21. 21.
    Josephs KA, Lin WL, Ahmed Z, Stroh DA, Graff-Radford NR, Dickson DW (2008) Frontotemporal lobar degeneration with ubiquitin-positive, but TDP-43-negative inclusions. Acta Neuropathol 116:159–167CrossRefPubMedGoogle Scholar
  22. 22.
    Knibb JA, Kipps CM, Hodges JR (2006) Frontotemporal dementia. Curr Opin Neurol 19:565–571CrossRefPubMedGoogle Scholar
  23. 23.
    Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, Valdmanis P, Rouleau GA, Hosler BA, Cortelli P, de Jong PJ, Yoshinaga Y, Haines JL, Pericak-Vance MA, Yan J, Ticozzi N, Siddique T, Kenna-Yasek D, Sapp PC, Horvitz HR, Landers JE, Brown RH Jr (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323:1205–1208CrossRefPubMedGoogle Scholar
  24. 24.
    Lagier-Tourenne C, Cleveland DW (2009) Rethinking ALS: the FUS about TDP-43. Cell 136:1001–1004CrossRefPubMedGoogle Scholar
  25. 25.
    Lindquist SG, Braedgaard H, Svenstrup K, Isaacs AM, Nielsen JE (2008) Frontotemporal dementia linked to chromosome 3 (FTD-3)—current concepts and the detection of a previously unknown branch of the Danish FTD-3 family. Eur J Neurol 15:667–670CrossRefPubMedGoogle Scholar
  26. 26.
    Lipton AM, White CL III, Bigio EH (2004) Frontotemporal lobar degeneration with motor neuron disease-type inclusions predominates in 76 cases of frontotemporal degeneration. Acta Neuropathol 108:379–385CrossRefPubMedGoogle Scholar
  27. 27.
    Luty AA, Kwok JB, Thompson EM, Blumbergs P, Brooks WS, Loy CT, Dobson-Stone C, Panegyres PK, Hecker J, Nicholson GA, Halliday GM, Schofield PR (2008) Pedigree with frontotemporal lobar degeneration—motor neuron disease and Tar DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9. BMC Neurol 8:32CrossRefPubMedGoogle Scholar
  28. 28.
    Mackenzie IR, Baborie A, Pickering-Brown S, Du PD, Jaros E, Perry RH, Neary D, Snowden JS, Mann DM (2006) Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathol 112:539–549CrossRefPubMedGoogle Scholar
  29. 29.
    Mackenzie IR, Foti D, Woulfe J, Hurwitz TA (2008) Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions. Brain 131:1282–1293CrossRefPubMedGoogle Scholar
  30. 30.
    Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE, Ince PG, Kamphorst W, Revesz T, Rozemuller AJ, Kumar-Singh S, Akiyama H, Baborie A, Spina S, Dickson DW, Trojanowski JQ, Mann DM (2009) Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol 117:15–18CrossRefPubMedGoogle Scholar
  31. 31.
    Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE, Ince PG, Kamphorst W, Revesz T, Rozemuller AJ, Kumar-Singh S, Akiyama H, Baborie A, Spina S, Dickson DW, Trojanowski JQ, Mann DM (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 119:1–4CrossRefPubMedGoogle Scholar
  32. 32.
    Mackenzie IR, Shi J, Shaw CL, Duplessis D, Neary D, Snowden JS, Mann DM (2006) Dementia lacking distinctive histology (DLDH) revisited. Acta Neuropathol 112:551–559CrossRefPubMedGoogle Scholar
  33. 33.
    McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ (2001) Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick’s Disease. Arch Neurol 58:1803–1809CrossRefPubMedGoogle Scholar
  34. 34.
    Munoz DG, Neumann M, Kusaka H, Yokota O, Ishihara K, Terada S, Kuroda S, Mackenzie IR (2009) FUS pathology in basophilic inclusion body disease. Acta Neuropathol 118:617–627CrossRefPubMedGoogle Scholar
  35. 35.
    Munoz-Garcia D, Ludwin SK (1984) Classic and generalized variants of Pick’s disease: a clinicopathological, ultrastructural, and immunocytochemical comparative study. Ann Neurol 16:467–480CrossRefPubMedGoogle Scholar
  36. 36.
    Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51:1546–1554PubMedGoogle Scholar
  37. 37.
    Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IR (2009) A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132:2922–2931CrossRefPubMedGoogle Scholar
  38. 38.
    Neumann M, Roeber S, Kretzschmar HA, Rademakers R, Baker M, Mackenzie IR (2009) Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol 118:605–616CrossRefPubMedGoogle Scholar
  39. 39.
    Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130–133CrossRefPubMedGoogle Scholar
  40. 40.
    Pirici D, Vandenberghe R, Rademakers R, Dermaut B, Cruts M, Vennekens K, Cuijt I, Lubke U, Ceuterick C, Martin JJ, Van Broeckhoven C, Kumar-Singh S (2006) Characterization of ubiquitinated intraneuronal inclusions in a novel Belgian frontotemporal lobar degeneration family. J Neuropathol Exp Neurol 65:289–301PubMedGoogle Scholar
  41. 41.
    Rademakers R, Cruts M, Van Broeckhoven C (2004) The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Hum Mutat 24:277–295CrossRefPubMedGoogle Scholar
  42. 42.
    Roeber S, Mackenzie IR, Kretzschmar HA, Neumann M (2008) TDP-43-negative FTLD-U is a significant new clinico-pathological subtype of FTLD. Acta Neuropathol 116:147–157CrossRefPubMedGoogle Scholar
  43. 43.
    Rohrer JD, Guerreiro R, Vandrovcova J, Uphill J, Reiman D, Beck J, Isaacs AM, Authier A, Ferrari R, Fox NC, Mackenzie IR, Warren JD, de Silva R, Holton J, Revesz T, Hardy J, Mead S, Rossor MN (2009) The heritability and genetics of frontotemporal lobar degeneration. Neurology 73:1451–1456CrossRefPubMedGoogle Scholar
  44. 44.
    Rosso SM, Donker KL, Baks T, Joosse M, de Koning I, Pijnenburg Y, de Jong D, Dooijes D, Kamphorst W, Ravid R, Niermeijer MF, Verheij F, Kremer HP, Scheltens P, van Duijn CM, Heutink P, van Swieten JC (2003) Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain 126:2016–2022CrossRefPubMedGoogle Scholar
  45. 45.
    Sampathu DM, Neumann M, Kwong LK, Chou TT, Micsenyi M, Truax A, Bruce J, Grossman M, Trojanowski JQ, Lee VMY (2006) Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol 169:1343–1352CrossRefPubMedGoogle Scholar
  46. 46.
    Seelaar H, Klijnsma KY, de Koning I, van der Lugt A, Chiu WZ, Azmani A, Rozemuller AJ, van Swieten JC (2009) Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration. J Neurol 257:747–753CrossRefPubMedGoogle Scholar
  47. 47.
    Seelaar H, Schelhaas HJ, Azmani A, Kusters B, Rosso S, Majoor-Krakauer D, de Rijik MC, Rizzu P, ten Brummelhuis M, van Doorn PA, Kamphorst W, Willemsen R, van Swieten JC (2007) TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutations. Brain 130:1375–1385CrossRefPubMedGoogle Scholar
  48. 48.
    Shi J, Shaw CL, Du PD, Richardson AM, Bailey KL, Julien C, Stopford C, Thompson J, Varma A, Craufurd D, Tian J, Pickering-Brown S, Neary D, Snowden JS, Mann DM (2005) Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation. Acta Neuropathol 110:501–512CrossRefPubMedGoogle Scholar
  49. 49.
    Skibinski G, Parkinson NJ, Brown JM, Chakrabarti L, Lloyd SL, Hummerich H, Nielsen JE, Hodges JR, Spillantini MG, Thusgaard T, Brandner S, Brun A, Rossor MN, Gade A, Johannsen P, Sorensen SA, Gydesen S, Fisher EM, Collinge J (2005) Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 37:806–808CrossRefPubMedGoogle Scholar
  50. 50.
    Snowden JS, Neary D, Mann DM (2002) Frontotemporal dementia. Br J Psychiatry 180:140–143CrossRefPubMedGoogle Scholar
  51. 51.
    Tsuchiya K, Ishizu H, Nakano I, Kita Y, Sawabe M, Haga C, Kuyama K, Nishinaka T, Oyanagi K, Ikeda K, Kuroda S (2001) Distribution of basal ganglia lesions in generalized variant of Pick’s disease: a clinicopathological study of four autopsy cases. Acta Neuropathol 102:441–448PubMedGoogle Scholar
  52. 52.
    Urwin H, Ghazi-Noori S, Collinge J, Isaacs A (2009) The role of CHMP2B in frontotemporal dementia. Biochem Soc Trans 37:208–212CrossRefPubMedGoogle Scholar
  53. 53.
    van der Zee J, Pirici D, Van Langenhove T, Engelborghs S, Vandenberghe R, Hoffmann M, Pusswald G, Van den Broeck M, Peeters K, Mattheijssens M, Martin JJ, De Deyn PP, Cruts M, Haubenberger D, Kumar-Singh S, Zimprich A, Van Broeckhoven C (2009) Clinical heterogeneity in 3 unrelated families linked to VCP p.Arg159His. Neurology 73:626–632CrossRefPubMedGoogle Scholar
  54. 54.
    van der Zee J, Urwin H, Engelborghs S, Bruyland M, Vandenberghe R, Dermaut B, De PT, Peeters K, Santens P, De Deyn PP, Fisher EM, Collinge J, Isaacs AM, Van BC (2008) CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro. Hum Mol Genet 17:313–322PubMedGoogle Scholar
  55. 55.
    Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, Ganesalingam J, Williams KL, Tripathi V, Al-Saraj S, Al-Chalabi A, Leigh PN, Blair IP, Nicholson G, de Belleroche J, Gallo JM, Miller CC, Shaw CE (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323:1208–1211CrossRefPubMedGoogle Scholar
  56. 56.
    Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, Pestronk A, Whyte MP, Kimonis VE (2004) Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 36:377–381CrossRefPubMedGoogle Scholar
  57. 57.
    Woulfe J, Gray DA, Mackenzie IR (2009) FUS-Immunoreactive Intranuclear Inclusions in Neurodegenerative Disease. Brain Pathol (in press)Google Scholar
  58. 58.
    Yokota O, Tsuchiya K, Terada S, Ishizu H, Uchikado H, Ikeda M, Oyanagi K, Nakano I, Murayama S, Kuroda S, Akiyama H (2008) Basophilic inclusion body disease and neuronal intermediate filament inclusion disease: a comparative clinicopathological study. Acta Neuropathol 115:561–575CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2010

Authors and Affiliations

  • Hazel Urwin
    • 1
  • Keith A. Josephs
    • 5
  • Jonathan D. Rohrer
    • 2
  • Ian R. Mackenzie
    • 7
  • Manuela Neumann
    • 8
  • Astrid Authier
    • 1
  • Harro Seelaar
    • 9
  • John C. Van Swieten
    • 9
  • Jeremy M. Brown
    • 10
  • Peter Johannsen
    • 11
  • Jorgen E. Nielsen
    • 11
    • 12
  • Ida E. Holm
    • 13
  • The FReJA Consortium
  • Dennis W. Dickson
    • 14
  • Rosa Rademakers
    • 14
  • Neill R. Graff-Radford
    • 14
  • Joseph E. Parisi
    • 6
  • Ronald C. Petersen
    • 5
  • Kimmo J. Hatanpaa
    • 15
  • Charles L. White III
    • 15
  • Myron F. Weiner
    • 16
  • Felix Geser
    • 17
  • Vivianna M. Van Deerlin
    • 17
  • John Q. Trojanowski
    • 17
  • Bruce L. Miller
    • 18
  • William W. Seeley
    • 18
  • Julie van der Zee
    • 19
    • 20
  • Samir Kumar-Singh
    • 19
    • 20
  • Sebastiaan Engelborghs
    • 20
    • 21
  • Peter P. De Deyn
    • 20
    • 21
  • Christine Van Broeckhoven
    • 19
    • 20
  • Eileen H. Bigio
    • 22
  • Han-Xiang Deng
    • 23
  • Glenda M. Halliday
    • 24
  • Jillian J. Kril
    • 25
  • David G. Munoz
    • 26
  • David M. Mann
    • 27
  • Stuart M. Pickering-Brown
    • 28
  • Valerie Doodeman
    • 29
  • Gary Adamson
    • 1
  • Shabnam Ghazi-Noori
    • 1
  • Elizabeth M. C. Fisher
    • 3
  • Janice L. Holton
    • 4
  • Tamas Revesz
    • 4
  • Martin N. Rossor
    • 2
  • John Collinge
    • 1
    • 3
  • Simon Mead
    • 1
  • Adrian M. Isaacs
    • 1
  1. 1.MRC Prion UnitUCL Institute of NeurologyLondonUK
  2. 2.Dementia Research CentreUCL Institute of NeurologyLondonUK
  3. 3.Department of Neurodegenerative DiseaseUCL Institute of NeurologyLondonUK
  4. 4.Department of NeuropathologyUCL Institute of NeurologyLondonUK
  5. 5.Department of NeurologyMayo ClinicRochesterUSA
  6. 6.Department of Laboratory Medicine and PathologyMayo ClinicRochesterUSA
  7. 7.Department of Pathology and Laboratory Medicine, Vancouver General HospitalUniversity of British ColumbiaVancouverCanada
  8. 8.Institute of NeuropathologyUniversity Hospital of ZurichZurichSwitzerland
  9. 9.Department of NeurologyErasmus University Medical Center RotterdamRotterdamThe Netherlands
  10. 10.Department of NeurologyAddenbrooke’s HospitalCambridgeUK
  11. 11.Memory Disorders Research Unit, Department of NeurologyCopenhagen University HospitalCopenhagenDenmark
  12. 12.Department of Cellular and Molecular Medicine, Section of Neurogenetics, The Panum InstituteUniversity of CopenhagenCopenhagenDenmark
  13. 13.Department of Pathology, Randers Hospital, Randers and Laboratory for Experimental Neuropathology, Danish Neuroscience CenterAarhus University HospitalAarhusDenmark
  14. 14.Department of NeuroscienceMayo ClinicJacksonvilleUSA
  15. 15.Department of PathologyUniversity of Texas Southwestern Medical SchoolDallasUSA
  16. 16.Departments of Psychiatry and NeurologyUniversity of Texas Southwestern Medical SchoolDallasUSA
  17. 17.Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory MedicineUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  18. 18.UCSF Department of NeurologyMemory and Aging CenterSan FranciscoUSA
  19. 19.VIB Department of Molecular GeneticsNeurodegenerative Brain Diseases GroupAntwerpenBelgium
  20. 20.Institute Born-BungeUniversity of AntwerpAntwerpenBelgium
  21. 21.Department of Neurology, Memory ClinicZNA MiddelheimAntwerpenBelgium
  22. 22.Department of Pathology, Feinberg School of MedicineNorthwestern UniversityChicagoUSA
  23. 23.Department of Neurology and Clinical Neurosciences, Feinberg School of MedicineNorthwestern UniversityChicagoUSA
  24. 24.Prince of Wales Medical Research InstituteUniversity of New South WalesSydneyAustralia
  25. 25.Disciplines of Medicine and PathologyUniversity of SydneySydneyAustralia
  26. 26.Department of Pathology, Saint Michael’s HospitalUniversity of TorontoTorontoCanada
  27. 27.Clinical Neuroscience Research Group, School of Translational Medicine, Greater Manchester Neurosciences CentreUniversity of ManchesterSalfordUK
  28. 28.Clinical Neurosciences Research Group, Faculty of Human and Medical SciencesUniversity of ManchesterManchesterUK
  29. 29.Department of Clinical GeneticsVU University Medical CenterAmsterdamThe Netherlands

Personalised recommendations